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2 
Abstract 13 
Recent work has demonstrated that the polyketide natural product Aurodox, from Streptomyces 14 
goldiniensis is able to block the pathogenesis of the murine pathogen Citrobacter rodentium. In 15 
this work we aimed to aimed gain a better understanding of the mechanism of action of the 16 
compound. We show that Aurodox downregulates the expression of the Type Three Secretion 17 
Systems of enteropathogenic and enterohaemorhagic Escherichia coli. Furthermore, we have 18 
used transcriptomic analysis to show that Aurodox inhibits the expression at the transcriptional 19 
level by repressing the master regulator, ler. Our data support a model in which Aurodox acts 20 
upstream of ler and not directly on the secretion system itself. Finally, we have shown that 21 
Aurodox, unlike some traditional antibiotics, does not induce expression of RecA, which is 22 
essential for the production of Shiga toxin. We propose that these properties nominate Aurodox 23 
as a promising anti-virulence therapy for the treatment of these infections. 24 
25 
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3 
Introduction  26 
Enterohaemorrhagic Escherichia coli (EHEC) is a zoonotic pathogen responsible for foodborne 27 
outbreaks of diarrhoea which can escalate to haemorrhagic colitis and Haemolytic Uraemic 28 
Syndrome (HUS) (1). Symptoms of Enteropathogenic Escherichia coli (EPEC) are typically less 29 
severe; however this pathotype remains the leading cause of diarrhoeal deaths in the developing 30 
world (2). As with many other Gram-negative pathogens, EHEC and EPEC utilise the Type Three 31 
Secretion System (T3SS) to promote host colonisation (3). The T3SS is a needle-like apparatus 32 
which facilitates the translocation of effector proteins to the epithelial cells of the gut. Through the 33 
injection of these proteins which include the Translocated Intimin Receptor (Tir) and the 34 
Mitochondria Associated Protein (Map), EHEC and EPEC are able to polymerise actin filaments 35 
and form intimate junctions with epithelial cells, where several other virulence factors are 36 
expressed to destabilize cellular processes (4, 5, 6). In the case of EHEC infection, symptoms 37 
can extend beyond the intestine as strains typically carry phage-derived Shiga toxins (Stx) which 38 
target organs such as the kidney and brain (7). This often leads to the life-threatening condition 39 
HUS (1).  40 
The T3SS of EHEC and EPEC is encoded by the highly-conserved Locus of Enterocyte 41 
Effacement (LEE) Island (8). This pathogenicity island encodes 42 genes on five conserved 42 
operons and is regulated by the master regulator, Ler. In turn, ler is regulated by specific 43 
regulators such as GrlA and GrlR, in addition to global regulators which mediate LEE expression 44 
in response to environmental stimuli (9).  45 
The reliance of EHEC and EPEC on the T3SS to initiate infection has identified it as a target for 46 
novel therapies to fight infection. Typically, these are part of a wider anti-virulence approach in 47 
which the aim is to prevent infection by the inhibition of a single virulence factor without inducing 48 
a reduction in growth (10). Currently, treatment of EHEC infections with traditional antibiotics is 49 
not recommended due to stimulation of the bacterial SOS response (11). In response to DNA 50 
damage caused by antibiotics, the SOS response protein, RecA is overexpressed which results 51 
in activation of the Stx-encoding phage (12). Hence, Stx production is upregulated and symptom 52 
severity increases. Additionally, the disruption to the native gut microbiome by broad-spectrum 53 
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4 
antibiotics can have negative consequences for the patient (13). As EHEC and EPEC infections 54 
are typically cleared naturally, anti-virulence approaches to treatment of EHEC and EPEC 55 
represent an exciting new strategy for the treatment of these infections. In addition, compounds 56 
that do not affect bacterial growth or survival reduce the evolutionary selective pressure on 57 
strains resistant to the treatment (10), enhancing the long-term viability of the therapy. 58 
Small compound inhibitors of the EPEC and EHEC T3SS have previously been identified 59 
(14)(15). Notably, the salicylidene acylhydrazide (SA) family have been shown to inhibit T3S in a 60 
range of enteric pathogens including EPEC, EHEC and Salmonella enterica (16). However, 61 
these compounds were found to bind to several bacterial protein targets and their mode of action 62 
has been shown to result from synergistic effects arising from a perturbation of the function of 63 
several conserved metabolic proteins (17). Therefore, the conclusion was that, although 64 
effective, the SAs were rather promiscuous (17).  65 
Several anti-virulence compounds are actually natural products of other bacterial species (16). 66 
Aurodox, a specialised metabolite of Streptomyces goldiniensis was shown by Kimura et al 67 
(2011) to inhibit the translocation of T3SS encoded effectors in EPEC, without effecting growth in 68 
vitro. Low concentrations (1.5 µM) were shown to inhibit secretion and abolition of detectable 69 
effector proteins was observed at 6 µM. Moreover, the effect of the compound in vivo was tested 70 
through the use of a Citrobacter rodentium murine infection model where it was shown that mice 71 
treated with the compound survived lethal infections with limited effects on the intestinal tract. 72 
Although the effects of the compound on T3S in EPEC were characterised, the wider effects and 73 
the mechanism of action of the compound were not elucidated (18). Therefore, there is a need to 74 
gain a better understanding of the mechanism of action of Aurodox. 75 
Aurodox was originally discovered in 1973 as an antibiotic compound with antibacterial effects 76 
upon Gram-positive pathogens such as Streptococcus pyogenes and Staphylococcus aureus 77 
(19). Aurodox has since been well-characterised in terms of its bactericidal mechanism, with a 78 
mild effect upon E. coli growth reported using concentrations greater than 1 mg/ml, 200 times 79 
higher than used in T3S assays (5 µg/ml) (20). Volgely et al (2001) determined the crystal 80 
structure of Aurodox bound to the Elongation Factor Thermo-Unstable (Ef-tu) of Thermus 81 
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5 
thermophilus, which confirmed their hypothesis that Aurodox initiated a conformational change in 82 
Ef-tu which prevented it from dissociating from the ribosome, blocking elongation activity (21). 83 
The limited spectrum of antibiotic activity of Aurodox has resulted in it being rejected as an 84 
antibiotic to treat infections in humans, yet the discovery of the novel T3SS inhibitory properties 85 
suggests Aurodox may be a candidate drug for repurposing.  86 
In this study, we characterise the effect of Aurodox on T3S in EHEC O157:H7 (TUV93-0), EPEC 87 
O127:H6 (E2348/69) and Citrobacter rodentium (ICC168) demonstrating that the Aurodox effects 88 
are independent of growth. Furthermore, we used transcriptomic analysis to show that Aurodox 89 
inhibits the T3SS at the level of transcription by repression of the LEE master regulator, ler. 90 
Furthermore, we suggest a model in which Aurodox acts upstream of Ler and not directly on the 91 
T3SS itself. Finally, we show that Aurodox does not induce expression of RecA, which is 92 
essential for the production of Stx. We propose that these properties make Aurodox a candidate 93 
anti-virulence therapy for the treatment of EPEC and EHEC infections. 94 
Materials and Methods 95 
Bacterial strains, plasmids and growth conditions: The strains used in this study are detailed 96 
in Supporting Information Table S1. The plasmids used in this study are described in Table S2. 97 
To induce T3SS expression, EHEC TUV93-0 was grown in MEM-HEPES (Sigma, St Louis, MO, 98 
USA) with 5.62 g/L L-glutamine and EPEC was grown in Glutamax-DMEM (Sigma) at 37°C at 99 
180 rpm. C. rodentium was also grown in Glutamax-DMEM (Sigma) and was cultured statically at 100 
37°C with 5% CO2. Growth and cell viability assays were carried out in Lysogeny Broth. For 101 
selection of plasmids, chloramphenicol or ampicillin were included at 20 and 50 μg/ml 102 
respectively. 103 
Acquisition and storage of Aurodox: Aurodox was purchased in its pure form (Enzo Life 104 
Sciences, Farmingdale, NY, USA). A 1 mg/ml stock solution was prepared by dissolving the 105 
compound in Dimethyl Sulphoxide (DMSO). The overall concentration of DMSO was < 0.5% in 106 
all experiments. We also purified Aurodox directly from S. goldiniensis according to Berger et al., 107 
(1973) and found the same effects. However, for consistency we used commercially available 108 
Aurodox. 109 
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6 
Analysis of secreted proteins: Overnight cultures were used to inoculate each strain into the 110 
appropriate, pre-warmed media to an initial OD600 of 0.05. The strains were grown with 111 
increasing concentrations of Aurodox to an OD600 = 0.7-0.9 before being centrifuged at 3800 rpm 112 
for 10 minutes to separate the cell mass. Cell lysates were prepared using BugBuster Protein 113 
Extraction Buffer™ (Merck, New Jersey, USA). The supernatant was removed, and proteins 114 
were precipitated by the addition of Trichloroacetic acid to a concentration of 10%, and 115 
incubation overnight at 4°C. The suspension was centrifuged at 3800 × g for one hour to form a 116 
protein pellet which was suspended in 100 µL Tris-HCL (pH 8.0). The samples were then mixed 117 
1:1 with loading dye (Novex, Waltham, Massachusetts, USA) and run on a 4-12% SDS-PAGE 118 
gel at 120V for 1 hour. Gels were subsequently stained with Coomassie Brilliant Blue stain 119 
(Novex, Waltham, Massachusetts, USA) and destained in water overnight. When required, bands 120 
were excised for subsequent in-gel digestion and analysis. Proteins analysed by tandem mass 121 
spectrometry were given a MASCOT score to indicate the probability of the identification being 122 
correct. 123 
Analysis of the effect of Aurodox on in vitro growth and cell viability: Overnight cultures of 124 
EHEC (TUV93-0), EPEC (E2348/69) and C. rodentium (ICC186) were used to inoculate 200 ml 125 
Erlenmeyer flasks containing 50 ml of LB broth ± 5 µg/ml Aurodox to an initial OD600 of 0.05. This 126 
was carried out in triplicate. At each time point, 100 µL of culture was removed, diluted 1/10 in LB 127 
media and the OD600 was measured by spectrophotometry. The standard error mean of optical 128 
densities was calculated, and a standard curve was plotted using Graph Pad Prism. The lines 129 
were fitted according to Weilbul formula and error bars were plotted as standard deviation from 130 
the mean. P values were determined using an unpaired t-test. For cell viability assays, each 131 
strain was grown to and OD600 of 3.0 both with and without Aurodox and colony forming units 132 
were determined through the serial dilution method. 133 
Infection of HeLa epithelial cells with EHEC O157:H7: A 24-well tissue culture plate 134 
containing coverslips was seeded with 107 HeLa cells in MEM-HEPES containing 5.62 g/L L-135 
glutamine and 10% Foetal Calf Serum. These were left to grow overnight. In parallel, two 136 
cultures of TUV93-0 prpsM-gfp (± 5 µg/ml Aurodox) were grown in 5 ml volumes under T3SS-137 
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7 
inducing conditions until OD600 = 0.6. The HeLa cells were washed once with PBS before 500 µL 138 
of fresh MEM-HEPES (± 5 µg/ml Aurodox) was added, in addition to 15 µL of bacterial culture. 139 
The plate was then centrifuged at 250 × g for three minutes and was left to incubate initially for 140 
one hour. Serial dilutions of the inoculum were carried out and spotted on to LB agar to 141 
determine the colony forming units (as above). After the initial hour, cells were washed three 142 
times with sterile PBS and 600 µL of fresh MEM-HEPES ± 5 µg/mL Aurodox was added before 143 
incubating for a further three hours. To quantify the adherent EHEC bacteria on treated and 144 
untreated cells, the cells were washed four times with sterile PBS and lysed through the addition 145 
of 1% Triton in PBS and incubation at room temperature for 10 minutes. Serial dilutions were 146 
spotted on LB agar to determine the adherent CFU. Colonisation efficiency was calculated as a 147 
percentage of the initial inoculum. To visualise the infections using Wide field Epifluorescent 148 
microscopy, cells on coverslips were fixed with 4% paraformaldehyde (20 minutes at room 149 
temperature) before permabilisation with 0.1% Triton in PBS (5 minutes at room temperature) 150 
and staining with Phalloidin Alexa-555 (Thermo-Fischer; 1 in 500 dilution, 1 hour at room 151 
temperature). Cells were mounted using Vectasheild with DAPI and sealed with clear nail polish. 152 
Images were acquired at 400 × magnification on a Zeiss Axioimager M1. For representative 153 
images, 11 z-slices of 0.55 μm were acquired before deconvolution using default settings in 154 
Zeiss Zen Pro software. Host cells were classified as infected if any bacteria were seen to be 155 
associated with them. 156 
mRNA extraction: EHEC (TUV93-0) was cultured as described above in triplicate, both with and 157 
without 5 µg/ml Aurodox. The cultures were mixed with two volumes of RNAprotect reagent 158 
(Qiagen, Valencia, CA, USA) at room temperature before being centrifuged at 3800 × g to 159 
harvest a cell pellet. RNeasy kit (Qiagen) was used to extract total RNA before TURBO DNase 160 
(Ambion, Carlsbad, CA, USA) was used to remove genomic DNA. Furthermore, a 161 
MICROBExpress mRNA enrichment kit (Ambion) was used to enrich samples for mRNA. The 162 
quality of the mRNA was determined using an Agilent Bioanalyzer 2100 at the University of 163 
Glasgow, Polyomics Facility. 164 
 o
n
 D
ecem
ber 5, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
   
 
   
 
8 
Transcriptome analysis using RNA sequencing: cDNA synthesis and sequencing was 165 
performed at the University of Glasgow Polyomics Facility (Illumina NextSeq 500) obtaining 75 or 166 
100 bp single end reads. Treated and untreated samples were sequenced in triplicate. FastQC 167 
(Babraham Bioinformatics, Cambridge, UK) was used to for quality control. Reads were trimmed 168 
accordingly using CLC Genomics Workbench (CLC Bio, Aarhus, Denmark). Trimmed reads were 169 
mapped to the EDL933 reference genome (NCBI accession number: NC_002655.2) allowing for 170 
3 mismatches per read and at least 5 reads per feature. Analysis of differential expression was 171 
performed using the Empirical analysis of DGE tool, which implements the EdgeR Bioconductor 172 
tool. Differentially expressed genes were identified using a positive or negative absolute fold 173 
change of ≥ 1.5 and a corrected P value of ≤ 0.05 (false-discovery rate of 5%). GO functional 174 
grouping was summarized according to information available on Colibase and the RegulonDB. 175 
Figures were generated using Graph pad Prism and Microsoft Excel. 176 
In vitro GFP fusion reporter assays: Electro-competent EHEC, EPEC and C. rodentium cells 177 
were transformed with the promoter-gfp reporter plasmids listed in Table (S2). The transformants 178 
were inoculated in to 10 ml of the appropriate media and cultured as previously stated. Samples 179 
were removed at indicated time-points to take measurements of optical density (OD600). To 180 
determine the overall fluorescence, 200 µL of culture was transferred in to a black 96-well plate 181 
and fluorescence was read with excitation of 485 nm and emission at 550 nm, using the 182 
FLUOstar Optima Fluorescence Plate Reader system (BMG Labtech, UK). This was carried out 183 
in triplicate. To determine the normalised fluorescence value, the background fluorescence 184 
intensity from untransformed cells was first subtracted and the subsequent values were 185 
normalised by dividing fluorescence by OD600. The data are the mean of the three samples and 186 
error bars represent the standard deviation. 187 
Overexpression of ler: Electro-competent EHEC cells were transformed with pVS45 plasmid 188 
containing ler gene under an arabinose-induced promoter and grown on 50 µg/ml ampicillin. A 189 
transformant colony was then used to prepare an overnight culture, which was subsequently 190 
inoculated into T3SS-inducing conditions as described above. At OD600 = 0.2, 2% arabinose was 191 
added. The supernatant protein fractions were then precipitated and analysed using SDS-PAGE 192 
 o
n
 D
ecem
ber 5, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
   
 
   
 
9 
as previously explained. Proteins for Western blot analysis were run on a 4-12% Bis-Tris gel and 193 
transferred to an Amersham ECL nitrocellulose membrane (GE Healthcare, Chicago, Il, USA) 194 
using the Nupage Novex gel transfer system (Invitrogen, Carlsbad, CA, USA). Blocking was then 195 
carried out using 5% skimmed milk powder in PBST. The membrane was then incubated with the 196 
anti-Tir primary antibody overnight in 1% milk powder/PBST buffer at a 1 in 1000 dilution. 197 
Antibodies for GroEL (AbCam) were used as a control for bacterial cell lysis at the same dilution. 198 
The following morning, the membrane was washed three times with PBST for ten minutes before 199 
being incubated for one hour with anti-mouse-HRP conjugated secondary antibody at a 1 in 2000 200 
dilution in 1% milk in PBST. The membrane was again washed three times with PBST. Finally, 201 
the membrane was developed with SuperSignal West Pico Chemiluminescent ECL (Thermo-202 
Fisher) substrate for five minutes before being transferred to a dark room in a cassette and 203 
exposed to x-ray film for thirty seconds.  204 
Detection of Shiga-toxin expression in C. rodentium DBS100 by Western Blot. 205 
C. rodentium DBS100 containing the Stx phage was cultured in 2 ml DMEM at 37 °C and 200 206 
rpm until OD600= 0.6. The whole cell fraction was removed from by centrifugation at 3800 x g for 207 
10 minutes. Secreted proteins were harvested as previously described. Proteins for Western blot 208 
analysis were run on a 4-12% Bis-Tris gel and transferred to an Amersham ECL PVDF 209 
membrane (GE Healthcare, Chicago, Il, USA) using the Nupage Novex gel transfer system 210 
(Invitrogen, Carlsbad, CA, USA). No blocking was carried out. The membrane was incubated 211 
with Anti-Stx (Beta Subunit) antibody (1/1000 concentration) overnight at 4 °C and washed three 212 
times with PBST. The membrane was incubated for one hour with anti-mouse-HRP conjugated 213 
secondary antibody at a 1 in 2000 dilution in 1% milk in PBST and washed three times with 214 
PBST. Finally, the membrane was developed with SuperSignal West Pico Chemiluminescent 215 
ECL (Thermo-Fisher) substrate for five minutes before being transferred to a dark room in a 216 
cassette and exposed to x-ray film for thirty minutes. 217 
 218 
Results: 219 
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10 
Aurodox inhibits the translocation of T3SS-associated effector proteins without 220 
affecting growth. 221 
In a previous study, Kimura et al (2011) demonstrated that Aurodox reduced the translocation of 222 
EPEC effector proteins in a concentration-dependant manner. We aimed to explore the effect of 223 
the compound on other LEE-encoding pathogens, primarily EHEC (TUV93-0) and C. rodentium 224 
(ICC168) and determine whether the mechanism of T3SS inhibition was independent of an 225 
inhibition in growth.  226 
Each strain was cultured in media appropriate for the expression of the T3SS (22). Aurodox was 227 
added to the cultures at the point of inoculation at increasing concentrations ranging from 1.5 228 
µg/ml to 5 µg/ml (1.2-6 µM) and bacteria were grown through 4 generations to an OD600 of 0.7-229 
0.9. Supernatant proteins were precipitated and whole cell lysates prepared as a comparator. 230 
The fractions were separated with SDS-PAGE and stained with Coomassie Brilliant Blue.  231 
For the supernatant fractions, a concentration dependant reduction in T3SS-associated effector 232 
proteins was observed (Figure 1A). The dominant bands from the gel were excised to permit in-233 
gel trypsin digestion and analysis by tandem mass spectrometry. This confirmed that, for all three 234 
pathogens, the two most dominant bands were comprised of three well-known effector proteins: 235 
Tir and EspB and EspD (Figure 1A, Table S3-5).In contrast, there was no change in the profile of 236 
the cellular proteins (Figure 1A), indicating that the mechanism was not due to a generic block in 237 
protein synthesis. Furthermore, these data allowed us to rule out an effect on general secretion 238 
as EspP, which is secreted in a Sec-dependant manner, was consistently detected in high 239 
abundance, even after Aurodox treatment (Table S4).  240 
At the highest concentration used (5 µg/ml) Aurodox does not inhibit growth of EPEC, EHEC or 241 
C. rodentium (Figure 1B). Importantly, no statistically significant decrease in cell viability was 242 
observed (data not shown). Therefore, at the concentration of Aurodox used, the mechanism of 243 
T3S inhibition is independent of any defect in growth or viability. This result confirms data by 244 
Kimura et al (2011) showing no effect of Aurodox on growth of EPEC and extends our 245 
understanding to the related pathogens, C. rodentium and EHEC. 246 
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11 
Aurodox inhibits the ability of EHEC to attach to and efface epithelial cells.  247 
Previous studies using a murine infection model tested the inhibitory effects of Aurodox on C. 248 
rodentium pathogenicity, demonstrating a marked improvement in the survival of infected mice 249 
and a reduction in colon damage when treated with Aurodox (18) however, the effects were not 250 
demonstrated at the cellular level.  251 
To investigate the effects of Aurodox on the attachment of EHEC to host cells, which is known to 252 
be driven via the T3SS we used an in vitro infection assay. The effect of Aurodox (5 µg/ml)  on 253 
uninfected HeLa cells was tested to confirm there was no overt cytotoxicity of the compound 254 
(Figure 2A). HeLa cells were infected with 107 EHEC bacteria constitutively expressing GFP. 255 
Host cell actin cytoskeleon was stained with Phalloidin-Alexa555. In addition, cell lysis was 256 
carried out to quantify the attached bacteria as a percentage of the initial innoculum. 257 
Epifluorescence microscopy images were used to quantify the infected cells and to investigate 258 
any effects on cell morphology. 259 
At a mutliplicity of infection of 150, untreated EHEC produced consistent infections with all HeLa 260 
cells showing adherent bacteria. The HeLa cells displayed morphological changes associated 261 
with bacterial infection including actin condensation caused by lesion formation and cell rounding 262 
(Figure 2A). Addition of Aurodox substantially reduced both phenotypes, with only 36 percent of 263 
cells becoming infected and a marked reduction in attaching and effacing lesions. Indeed, the 264 
infections by EHEC were typically restricted to a small number of bacteria per cell (< 5). 265 
Quantification of bacterial adherence efficiency by colony forming unit counts showed a greater 266 
than 3-log reduction in EHEC colonisation when treated with Aurodox (Figure 2C), demonstrating 267 
the potent anti-virulence capacity of Aurodox. 268 
Aurodox inhibits expression of multiple virulence genes including the Locus of 269 
Enterocyte Effacement (LEE). 270 
To gain insights into the possible molecular mechanism underlying the inhibition of the T3SS we 271 
used whole transcriptome analysis. EHEC was grown in MEM-HEPES ± 5 mg/ml Aurodox and 272 
RNA was extracted from triplicate cultures. Transcripts were mapped to the EHEC EDL933 273 
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12 
reference genome and the mean fold change was calculated. In total, 84 chromosomal genes 274 
and four pO157 genes were significantly downregulated (using a fold change of -1.5 and an 275 
EDGE test P value of < 0.05; Fig 3A and Table S6). Consistent with the secretion data, analysis 276 
of LEE transcription revealed downregulation of the island after treatment with Aurodox (Figure 277 
3B), with 25 of the 41 LEE genes significantly downregulated, including the master regulators ler 278 
and grlA (9) Figure 3A and B). Aurodox also repressed expression of genes encoding non-LEE 279 
encoded effector proteins secreted by the T3SS, such as NleB and EspG.  Moreover, there was 280 
no significant downregulation of genes encoding T3SS-independent effector proteins, such as 281 
EspP. 282 
The data also revealed that many genes in the colanic acid biosynthesis operon were 283 
downregulated in the presence of Aurodox. Our initial results show that 20 of the 21 genes in this 284 
operon are downregulated in response to Aurodox with 15 significant changes (P = 0.05; Table 285 
S6). Notably, expression of rcsA, a key regulator of colanic acid biosynthesis that is known to 286 
form part of the Ler dependent regulon (23) was downregulated 2.5-fold. These data suggest that 287 
suppression of the colonic acid operon is likely due to expression changes in the key regulators 288 
RcsA and Ler. These changes could indicate further potential of Aurodox for the treatment of 289 
EHEC infections, as colanic acid production is required in vivo during infection (24).   290 
In addition, 103 genes were upregulated in the presence of Aurodox which include various 291 
metabolic genes (prpR, trpA, trpB), and genes encoding sensory proteins (e.g. narQ). 292 
Importantly, there was no upregulation of SOS response- associated genes or virulence genes. 293 
The most upregulated gene was ecpD, a putative fimbrial chaperone protein, with a log2 fold 294 
change of 5. 295 
 296 
Aurodox inhibits T3SS expression through downregulation of the master regulator Ler.  297 
To confirm the virulence-related Aurodox targets identified by RNA-seq we used GFP gene 298 
reporter assays to validate observed changes in gene expression. GFP reporter plasmids for ler 299 
and the housekeeping gene rpsM were introduced into strains and fluorescence was measured 300 
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13 
during exponential phase. This showed that in EHEC expression of ler was significantly reduced 301 
in the presence of Aurodox (Figure 3C). There was no significant change in expression of the 302 
housekeeping gene, rpsM (Figure 3C), consistent with the RNA-seq data. A reduction in ler 303 
expression was also observed for EPEC (Supplementary Figures S1), implying a common 304 
mechanism by which Aurodox causes a reduction of T3SS expression.  305 
Overexpression of Ler overrides EHEC inhibition of the T3SS by Aurodox 306 
Inhibition of the T3SS by Aurodox could be explained by a number of mechanisms. These 307 
include: (1) Directly inhibiting Ler expression or function, (2) binding to a component of the T3SS 308 
resulting in negative feedback of ler or (3) affecting an upstream regulator of ler. To test if 309 
expression of structural components of the T3SS affected expression of Ler we used a series of 310 
EPEC deletion mutants in various apparatus proteins. The rationale being that if a structural 311 
component were a target of Aurodox, then this would have to result in downregulation of ler, and 312 
therefore the other genes in the T3SS and the wider Ler regulon. However, analysis of four 313 
structural components of the T3SS apparatus proteins showed that there was no effect on ler 314 
transcription when assayed using a GFP reporter (Figure 4A). Moreover, addition of Aurodox 315 
resulted in reduced expression of ler in both WT EHEC and an escC deletion mutant (Figure 4B). 316 
These data show that there is no apparent feedback from structural components on the 317 
expression of the master regulator of the T3SS itself and that Aurodox results in downregulation 318 
of ler, irrespective whether the T3SS is fully assembled or not. 319 
We then questioned if a regulator upstream or downstream of Ler was the target. To address 320 
this, EHEC was transformed with the pVS45 plasmid encoding ler under transcriptional control of 321 
an arabinose-inducible promoter (25). By selectively overproducing Ler we could test the 322 
sensitivity of EHEC to Aurodox-mediated T3SS inhibition. The transformed strain was grown in 323 
media to induce LEE expression both in the presence and absence of 5 µg/ml Aurodox and 2% 324 
arabinose to induce expression of Ler. The fractions were analysed using immunoblotting with 325 
antibodies against the T3SS protein Tir. In the absence of arabinose (uninduced Ler) the addition 326 
of Aurodox results in T3SS inhibition as seen in previous experiments (Figure 4C). However, 327 
overexpression of Ler by addition of arabinose completely overcomes the phenotype of T3SS-328 
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mediated repression normally associated with addition of Aurodox (Figure 4C). This result 329 
indicates that Aurodox acts by either directly acting on Ler or by a mechanism involving an 330 
upstream regulator of Ler.  331 
 332 
Aurodox does not induce the SOS response in EHEC. 333 
Antimicrobial compounds that induce DNA damage are known to stimulate the bacterial SOS 334 
response. A key protein in this regulon is RecA, a co-protease that functions in the autocatalytic 335 
cleavage of the LexA and the λ repressors resulting in derepression of approximately 40 genes 336 
involved in the SOS response and importantly, an increased expression of bacteriophage-337 
encoded Stx (26). As a potential treatment for EHEC infection, we therefore aimed to investigate 338 
if Aurodox had any undesirable effects on Stx expression. RNA-seq transcriptome data did not 339 
reveal differential expression of SOS regulated genes (as defined by Fernández et al (27) in 340 
response to Aurodox. To validate this, EHEC was transformed with a plasmid containing a 341 
precA-gfp fusion and gene expression measured over a time course (Figure 5). Ciprofloxacin 342 
was used a positive control of RecA expression and provided log-fold stimulation compared with 343 
the uninduced control (Figure 5). In contrast, the data show that Aurodox does not induce recA 344 
transcription in EHEC at four and eight-hour time points. (Figure 5). The data imply that addition 345 
of Aurodox does not induce the SOS response and therefore, by implication, Stx expression, 346 
enhancing the potential of the compound to be used as a treatment for EHEC infections. 347 
To test this hypothesis we directly examined the effect of Aurodox on Stx expression in vitro. To 348 
test this Citrobacter rodentium DBS100 was used. This strain has been lysogenized by an 349 
Stx2dact-producing phage and produces functional Stx. This strain was cultured in the presence 350 
of Aurodox, Ciprofloxacin and Aurodox and Ciprofloxacin. The secreted proteins were harvested 351 
and probed using an antibody for the beta subunit of the Shiga toxin (Figure 5B). The resulting 352 
bands showed that Aurodox does not induce the expression of Stx, in contrast to Ciprofloxacin,. 353 
These findings therefore enhance the potential of the compound to be used as a treatment for 354 
EHEC infections. 355 
 356 
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Discussion 357 
The central role of T3SSs in the pathogenesis of many bacterial species provides the impetus to 358 
develop strategies that interfere with their function. To this end, “virulence blockers” have been 359 
described that selectively target the expression or function of T3SSs in a number of bacterial 360 
species, including Y. pseudotuberculosis, Salmonella serovar Typhimurium and C. pneumoniae 361 
(28)(29). Whilst screening programmes can readily find compounds that inhibit the T3SS, 362 
identifying inhibitors that work both in vitro and in vivo with high selectivity has proven 363 
challenging. Therefore, the discovery that Aurodox could protect mice from a lethal infection with 364 
C. rodentium by Kimura et al (2011) was an important observation.  365 
In this study we attempted to address three questions. First, can Aurodox block the function of 366 
the T3SS in EHEC O157:H7, as well as EPEC and C. rodentium? This is important to address 367 
because there are very limited treatment options for EHEC infections due to complications 368 
associated with Shiga toxin expression. Second, are there inhibitor-specific transcriptional 369 
responses that may help us understand the mode of action? Thirdly, does Aurodox alter the 370 
bacterial the SOS response affecting expression of bacteriophage-encoded Stx? 371 
In agreement with Kimura et al, (2011) we observed that Aurodox resulted in a concentration 372 
dependent inhibition of T3S in EPEC and C. rodentium. The same result was found in EHEC, a 373 
result that shows a likely common mechanism of inhibition. Importantly, at the concentrations 374 
used, there were no effects on bacterial growth rate or viability in any of the species tested. This 375 
finding suggests that the mechanism by which Aurodox inhibits the T3SS is distinct from the 376 
reported target of bactericidal activity  elongation factor Tu (EF-Tu) (21), a vital component of the 377 
protein biosynthesis machinery. It is notable that Aurodox is an extremely poor antibiotic against 378 
E. coli, with previous work showing limited inhibition zones at 1 mg/ml; some 200× the 379 
concentrations used to inhibit the T3SS (30). Furthermore, the distinct nature of the mechanisms 380 
of T3S inhibition and bactericidal activity have positive implications for resistance. Although 381 
resistance to Aurodox as an antibiotic may arise through mutations in Ef-tu, these mutations 382 
would not confer resistance to Aurodox as an inhibitor of the T3SS or restore virulence. Although 383 
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it is possible mutations in ler or its regulators may result in resistance to Aurodox as a T3S 384 
inhibitor, these would not be strongly selected for in the same way as conventional antibiotics.  385 
Our transcriptomic data provides the first insight into how Aurodox affects global gene 386 
expression. Remarkably, only 3.24% of the genome showed a significant up or downshift in 387 
transcription. This shows excellent specificity and selectivity of inhibition, both very desirable 388 
qualities for an anti-virulence compound (10). Perhaps predictably, much of the LEE was seen to 389 
be downregulated, including transcription of the master regulators ler and grlA (9). Further, many 390 
of the genes affected were part of the Ler regulon suggesting a mode of action centred around 391 
this protein. Critically, overexpression of Ler, by an inducible expression system, completely 392 
over-rides the effects of Aurodox on secretion of Tir via the T3SS. Our data also confirm that 393 
deletion of components of the T3SS system, such as structural proteins, does not lead to 394 
transcriptional feedback on LEE1. In conjunction with the transcriptomics data, our working 395 
model is that Aurodox binds a target that affects transcription of ler. The complexity and high 396 
molecular weight of Aurodox suggests that the compound may have the ability to compromise 397 
the integrity of the outer membrane on cell entry, and hence activate the membrane stress 398 
response sigma factor, RpoE. Increased expression of this sigma factor has been reported to 399 
reduce T3S via downregulation of ler, particularly in the presence of Zinc (31). However, our 400 
transcriptomal analysis has shown 1.54-fold downregulation of the sigma factor, and therefore, 401 
we believe this pathway is unlinked.  Elucidating specific targets for anti-virulence compounds is 402 
often challenging (32) and proving a specific target for Aurodox would be problematic because it 403 
is a complex natural product making labelling or modification extremely difficult.  404 
We have also demonstrated, for the first time, that Aurodox does not stimulate expression of 405 
RecA, a key protein that helps mediate the SOS response in E. coli (33). The SOS response is 406 
known to be a key regulator of lambdoid bacteriophage transcription by stimulating autocleavage 407 
of the phage repressor, cI, in response to DNA damage, triggering a cascade that leads to 408 
transcription of the Q anti-terminator transcript and the lytic cycle(34). As both the stxA and stxB 409 
genes in EHEC strains are located on the genomes of resident prophages (35), it is not 410 
surprising that they are upregulated by the SOS response that can induced by treatments that 411 
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damage bacterial DNA, including UV light, selected antibiotics, and mitomycin C. This response 412 
to traditional broad-spectrum antibiotics has made treatment of EHEC problematic and highlights 413 
an important advantage of Aurodox: it can suppress virulence without the “sting in the tail” 414 
associated with Shiga toxin expression and damage.  415 
A further interesting aspect of Aurodox biology would be to explore any wider effects on the 416 
microbiota. The gut microbiota has long been recognized to contribute to health and disease by 417 
influencing gut maturation, host nutrition and pathogen resistance (36). Moreover, the density 418 
and diversity of the gut microbiota offers ample opportunities for the horizontal transfer of genetic 419 
material, including antibiotic resistance genes. Therefore, it would be important to understand if 420 
Aurodox was indeed highly targeted towards a small subset of pathogens or if it had any 421 
undesirable effects on the wider gut microbiota, which could be monitored using methods such 422 
as metagenomics. Overall, our work shows that Aurodox works in a highly-targeted manner that 423 
supports its strong consideration for re-purposing as treatment against EHEC infection in 424 
humans.  425 
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Figure legends: 439 
Figure 1. Aurodox inhibits secretion of T3SS-associated effector proteins in EPEC, EHEC 440 
and Citrobacter rodentium without effecting bacterial growth. (A) Secreted protein fractions 441 
were prepared by culturing strains in T3S-inducing media and precipitating from the supernatant 442 
using Trichloroacetic Acid. Whole cell fractions were prepared by lysis of cell pellets. Samples 443 
were resolved using SDS gel-electrophoresis followed by Coomassie staining. Marked protein 444 
bands were excised and trypsin-digested for Mass Spectrometry identification of proteins. (B) 445 
Aurodox does not inhibit the growth of EPEC, EHEC or C. rodentium in Type Three Secretion-446 
Inducing media. EHEC was grown in MEM-HEPES media and EPEC/ C. rodentium were grown 447 
in DMEM. Growth rates were determined spectrophotometrically (OD
600
), n = 3. Error bars 448 
plotted are standard deviation from the mean. Changes in growth were not statistically 449 
significant. 450 
Figure 2. Effect of Aurodox on EHEC infection of epithelial cells and A/E lesion formation. 451 
(A) Representative microscopy images from EHEC cell infection assay. Cells were infected with 452 
107 EHEC cells transformed with prpsM-gfp (green) to facilitate quantification and imaging. HeLa 453 
cells were actin-stained with Phaloidin-Alexa Fluor 555 (red) and mounted in Vectashield with 454 
DAPI (blue). Scale bar represents 50 μm. Inset panels contain a 4X magnification of the 455 
indicated area. (B) Colonisation was quantitated by counting the numbers of cells possessing 456 
EHEC on their surface and expressing as a percentage of the total. (C) Following infection, HeLa 457 
were washed to remove non-adherent bacteria and subsequently lysed to release colonised 458 
bacteria. The CFU of EHEC in the lysate was enumerated and colonisation efficiency was 459 
calculated by expressing as a percentage of the inoculum. Significance was calculated by paired 460 
Student’s t-test, (*, P < 0.05; **, P < 0.01). 461 
Figure 3. Transcriptional changes induced by Aurodox in EHEC. (A) Venn diagram 462 
representing overlap between genes significantly downregulated by Aurodox (> 1.5 fold, P < 463 
0.05) and LEE genes. (B) Heatmap representation of Log2 fold change in gene expression after 464 
treatment with Aurodox. (C) Effect of Aurodox on expression of ler and the housekeeping gene 465 
rpsM. Aurodox was added at 5 µg/ml and expression measured after 4 hours of growth. 466 
 o
n
 D
ecem
ber 5, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
   
 
   
 
19 
Expression of rpsM was not significantly altered in contrast to that of Ler (P = 0.009). Error bars 467 
plotted are equivalent to the SD from the mean, n  =3.  468 
Figure 4. Transcriptional repression of ler does not occur as a result of the interaction of 469 
Aurodox with the type three secretion needle. (A) Analysis of ler expression in EPEC mutants 470 
deleted for genes encoding structural components of the T3SS. Mutant strains were transformed 471 
with pler-gfp. Optical Density and fluorescence were measured at hourly intervals and ler 472 
expression was quantified in Relative Fluorescence Units (fluorescence/OD600). (B) Relative ler 473 
expression during exponential phase in WT EPEC vs EPEC ΔescC treated with Aurodox. 474 
Expression of ler in treated samples is expressed as a percentage of untreated samples. (C) 475 
Effect of Ler overexpression on the Aurodox phenotype. Arabinose was added to induce 476 
expression and the effect of Aurodox on Tir expression was determined by immunoblotting. 477 
Figure 5. Analysis of the effect of Aurodox on RecA-mediated Stx expression. (A) Analysis 478 
of in vitro recA-gfp expression in Aurodox-treated EHEC. Aurodox and ciprofloxacin were added 479 
at 6 µM. Error bars correspond to SD from the mean with n = 4. P values for Aurodox treated 480 
versus Ciprofloxicin treated were < 0.01. (B) Immunoblot analysis of Stx expression in untreated, 481 
Aurodox treated, Ciprofloxacin treated, and Aurodox + Ciprofloxacin treated C. rodentium 482 
DBS100. Primary antibodies for Shiga toxin B subunit (6 kDa) were used.  483 
484 
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